Antibody –drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

.

Source: Expert Opinion on Biological Therapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Lorenzo GuidiCarmine ValenzaDario TrapaniGiuseppe Curiglianoa Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italyb Department of Oncology and Hemato-Oncology, University of Milan, Source Type: research